profit from every $100 of sales.
$0$100
Korro Bio
$13.61-4.89% today
+109.4% in 1 year
1-year low $5.281-year high $16.62
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2024 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Korro Bio sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $6.39 million in 2025, with -$117 million of profit last year.
SalesProfit
Korro Bio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Korro Bio | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Korro Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 2 | 6 | |
| – | – | – | – | |
| -59 | -85 | -92 | -87 | |
| -56 | -81 | -88 | -83 | |
| -58 | -81 | -84 | -117 | |
| -7.25 | -53.08 | -9.37 | -12.48 | |
| – | – | – | – | |
| – | – | -4,047.1% | -1,366.4% | |
| – | – | -3,680.4% | -1,834.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 74 | 222 | 226 | 114 |
| Cash | 36 | 166 | 56 | 22 |
| Total debt | 3 | 33 | 45 | 43 |
| Total liabilities | 173 | 52 | 66 | 62 |
| -99 | 170 | 160 | 51 | |
| 8 | 2 | 9 | 9 | |
| – | -32.9% | -35.4% | -72.7% | |
| 58.6% | -47.8% | -52.1% | -228.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -54 | -67 | -60 | -79 | |
| 5 | 8 | 18 | 1 | |
| -59 | -75 | -78 | -79 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 2 | 4 | 8 |
Valuation
- –
- –
- –
- 0.9×
- 29.2×
- –
- –
- -42.3%
- -62.8%
- 0.0%
Profitability
- 73.2%
- -1,366.4%
- -1,834.5%
- -2,034.0%
- -48.2%
- -67.5%
- -117.9%
- -61.8%
- -49.0%
- 1,530.1%
Growth
- +181.5%
- –
- −1.4%
- –
- +20.6%
Financial health
- –
- 0.36
- 23.4%
- –
- 8.13
- 8.13
- 0.02
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 7%of 952
Top 2%of 887
Bottom 1%of 987
What analysts expect
- Average price target
- $20.29
- Range
- $10.00 – $30.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -1.69 | -1.60 | −5.6% |
| Mar 12, 2026 | -5.32 | -1.93 | −175.6% |
| Nov 12, 2025 | -1.92 | -2.61 | +26.4% |
| Aug 12, 2025 | -2.74 | -2.54 | −7.9% |
| May 7, 2025 | -2.49 | -2.60 | +4.2% |
| Mar 18, 2025 | -2.26 | -2.33 | +3.0% |
| Nov 12, 2024 | -2.26 | -2.55 | +11.4% |
| Aug 13, 2024 | -2.43 | -2.40 | −1.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
65Pass
Philip Fisher
48No pass
Peter Lynch
5No pass
Joel Greenblatt
0No pass
Charlie Munger
47No pass
Terry Smith
43No pass
Questions about Korro Bio
Is Korro Bio a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Korro Bio AI analysis
What does Korro Bio do?
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts. It is in Biotechnology.
Does Korro Bio pay a dividend?
No. Korro Bio does not pay a dividend at the moment.
Is Korro Bio stock halal?
Questionable. Korro Bio sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Korro Bio stock done over the past year?
Up 109.4% over the past twelve months, to $13.61. It traded between $5.28 and $16.62 and is 18.1% below its high.
Who are Korro Bio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Korro Bio's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.